News
An innovator in developing therapeutic antibodies, fusion proteins and circRNA
News
2026-01-29
T-Cell Immunotherapy Evolution: How CD3-VHH is Transforming TCEs, In Vivo TCEs, and In Vivo CAR-T Platforms
Read more 
2026-01-29
T-Cell Immunotherapy Evolution: How CD3-VHH is Transforming TCEs, In Vivo TCEs, and In Vivo CAR-T Platforms
Read more 
2026-01-08
Excellent Human-Monkey Cross-Reactivity !
This CD3-VHH Potently Accelerates the Clinical Translation of TCE Drugs
Read more
2025-12-23
Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
Read more
2025-08-06
Fapon Biopharma Announces the Enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors
Fapon Biopharma is delighted to announce the completion of the first patient enrollment in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tumors, at Zhejiang Cancer Hospital.
Read more
2025-06-11
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center.
Read more
2025-02-28
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
Read more
